Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer

Por STEFFENSEN, KARINA DAHL, WALDSTRØM, MARIANNE, BRANDSLUND, IVAN, LUND, BENTE, SØRENSEN, SARAH MEJER, PETZOLD, MAX, JAKOBSEN, ANDERS
Publicado no Oncol Lett (2016)

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensiti...

Por Wang, Yun, Herrstedt, Jørn, Havsteen, Hanne, DePoint Christensen, Rene, Mirza, Mansoor Raza, Lund, Bente, Maenpaa, Johanna, Kristensen, Gunnar
Publicado no BMC Cancer (2014)

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

Por del Campo, Josep M., Matulonis, Ursula A., Malander, Susanne, Provencher, Diane, Mahner, Sven, Follana, Philippe, Waters, Justin, Berek, Jonathan S., Woie, Kathrine, Oza, Amit M., Canzler, Ulrich, Gil-Martin, Marta, Lesoin, Anne, Monk, Bradley J., Lund, Bente, Gilbert, Lucy, Wenham, Robert M., Benigno, Benedict, Arora, Sujata, Hazard, Sebastien J., Mirza, Mansoor R.
Publicado no J Clin Oncol (2019)